Oklo Inc. (NYSE: OKLO) achieved a significant technical milestone with its Groves test reactor reaching criticality on August 5, 2026, in Lockhart, Texas. The event, confirmed by the Department of Energy (DOE), marks the fifth advanced reactor approved by the DOE to achieve this status this summer. The company completed construction and activation of the low-power test reactor in less than a year, demonstrating execution speed in a sector often plagued by delays.
However, the company's financials reveal a widening gap between its market valuation and its tangible assets. As of Thursday's close, Oklo's market capitalization stood at $7.19 billion, based on a share price of $42.19. The company's balance sheet at the end of June showed cash and marketable securities totaling $3.01 billion, leaving approximately $4.18 billion of market value attributable to future expectations rather than current resources.
Financial Performance and Cash Position
Oklo's second-quarter results, filed on Friday, show the cost of aggressive execution. Revenue reached $1.21 million, but the net loss widened to $48.54 million, nearly double the $24.69 million loss in the same period last year. Research and development expenses surged 244% year-over-year to $39.47 million, while general and administrative costs rose 107% to $34.21 million. The loss per share increased from $0.18 to $0.28.
Operating cash outflows for the first half totaled $65.46 million, with capital expenditures of approximately $126.9 million. To fund these activities, the company raised about $1.9 billion through at-the-market equity offerings during the first half, boosting its liquidity and expanding its equity base.
Valuation Bridge and Market Comparisons
The $4.18 billion gap between market cap and cash and securities represents the market's assessment of Oklo's licensing progress, construction execution, and future revenue potential. This valuation surpasses that of peer NuScale Power (NYSE: SMR) by over twofold, and is nearly eight times higher than Nano Nuclear Energy (NASDAQ: NNE). BWX Technologies (NYSE: BWXT) continues to command a larger market cap and posts positive trailing earnings.
Public nuclear company valuations vary widely, reflecting differences in reactor designs, fuel strategies, and business models. However, Oklo's premium suggests investors are assigning significant credit to its execution capabilities and regulatory momentum.
Technical Milestone and Commercial Hurdles
The Groves reactor, which is intended for future commercial isotope production rather than electricity generation, successfully initiated a controlled, self-sustaining chain reaction at low power. CEO Jacob DeWitte called it "an incredible milestone for our team." The company handled construction, procurement, fuel, and operations internally.
While this achievement addresses a specific execution risk, commercial power production and cost efficiency at scale remain unproven. The DOE's approval under its pilot scheme does not substitute for a full Nuclear Regulatory Commission (NRC) license. Developers must demonstrate that DOE assessments meet NRC standards and cover any subsequent design modifications.
Analyst Sentiment and Future Outlook
Wall Street remains divided on Oklo. MarketBeat's 23-analyst panel issues a "Moderate Buy" recommendation with an average price target of $88, ranging from $55 to $130. Recent actions include Barclays (LON: BARC) lowering its target to $76 from $82 on July 22, and Truist Financial (NYSE: TFC) initiating coverage with a Hold and $55 target. These recommendations were made before the criticality event and Friday's financial disclosure.
Key risks include the possibility that Groves may not significantly reduce NRC review times, the need for additional financing for commercial plants, potential dilution from future share issuances, and the uncertainty that positive test results will translate into strong margins. Investors are now focused on the company's ability to convert technical achievements into commercial success.
